Brepocitinib
Small moleculeexperimental
Clinical trial activity
26 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
16
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02310750)
Timeline
Indications
Studied for
- Alopecia · Phase 2
- Alopecia Areata · Phase 2
- Arthritis, Psoriatic · Phase 2
- Colitis, Ulcerative · Phase 2
- Crohn Disease · Phase 2
- Dermatitis, Atopic · Phase 2
- Dermatomyositis · Phase 3
- Healthy Volunteers · Phase 1
- Hidradenitis Suppurativa · Phase 2
- Kidney Failure, Chronic · Phase 1
- Ligaments, Articular · Phase 1
- Lupus Erythematosus, Systemic · Phase 2
- Psoriasis · Phase 2
- Sarcoidosis · Phase 2
- Uveitis · Phase 3
- Uveitis, Intermediate · Phase 3
- Uveitis, Posterior · Phase 3
- Vitiligo · Phase 2
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
- Tyrosine-protein kinase JAK1INHIBITOR
Tyrosine-protein kinase JAK1 inhibitor
Lower activity against Jak2
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1- Mol. weight
- 389.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297477 ↗
Also known as
- pf-06700841
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06978725 | Phase 2 | Apr 9, 2025 | Priovant Therapeutics, Inc. |
| NCT06431373 | Phase 3 | Sep 11, 2024 | Priovant Therapeutics, Inc. |
| NCT06433999 | Phase 2 | Aug 31, 2024 | Mayo Clinic, Priovant Therapeutics, Inc. |
| NCT05523765 | Phase 2 | Nov 14, 2022 | Priovant Therapeutics, Inc. |
| NCT05437263 | Phase 3 | Oct 31, 2022 | Priovant Therapeutics, Inc. |
| NCT05076006 | Phase 2 | May 21, 2021 | Icahn School of Medicine at Mount Sinai, Pfizer |
| NCT04580797 | Phase 1 | Oct 2, 2020 | Pfizer |
| NCT04267250 | Phase 1 | Mar 19, 2020 | Pfizer |
| NCT04260464 | Phase 1 | Mar 5, 2020 | Pfizer |
| NCT04092452 | Phase 2 | Nov 11, 2019 | Pfizer |
| NCT04090047 | Phase 1 | Sep 16, 2019 | Pfizer |
| NCT03963401 | Phase 2 | Jun 13, 2019 | Pfizer |
| NCT03903822 | Phase 2 | May 13, 2019 | Pfizer |
| NCT03845517 | Phase 2 | Apr 18, 2019 | Pfizer |
| NCT03850483 | Phase 2 | Apr 8, 2019 | Pfizer |
| NCT03916250 | Phase 1 | Mar 23, 2019 | Pfizer |
| NCT03765554 | Phase 1 | Jan 7, 2019 | Pfizer |
| NCT03770039 | Phase 1 | Dec 10, 2018 | Pfizer |
| NCT03715829 | Phase 2 | Nov 26, 2018 | Pfizer |
| NCT03656952 | Phase 1 | Sep 5, 2018 | Pfizer |
Showing 20 of 26 trials
Page 1 / 2
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 21 | 20 | 2 | 2014 |
| Priovant Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2022 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1